Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1766 • ACR Convergence 2020
Trends of Pregnancy Outcomes in a Large Electronic Health Record Cohort of Systemic Lupus Erythematosus Patients
April Barnado¹, Alex Camai¹ and Lee Wheless¹, ¹Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Studying pregnancy in systemic lupus erythematosus (SLE) is difficult given its relative rarity. Electronic health record (EHR) contain longitudinal data to serve as a…
Abstract Number: 1797 • ACR Convergence 2020
A Multianalyte Assay Panel (MAP) with Algorithm Containing Cell-Bound Complement Activation Products (CB-CAPs) Is Superior to Anti-dsDNA and Low Serum Complement Levels in Predicting Transition of Probable Lupus to ACR Classified Lupus Within 2 Years
Rosalind Ramsey-Goldman¹, Roberta Vezza Alexander², Cristina Arriens³, Sonali Narain⁴, Elena Massarotti⁵, Daniel J Wallace⁶, Amit Saxena⁷, Christopher Collins⁸, Chaim Putterman⁹, Kenneth Kalunian¹⁰, Armida Sace², Rowena LaFon², JoAnne Ligayon², John Conklin¹¹ and Arthur Weinstein¹², ¹Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Exagen Inc, Vista, CA, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Northwell Health, Great Neck, NY, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Cedars-Sinai Medical Center, Beverly Hills, CA, ⁷NYU School of Medicine, New York, ⁸MedStar Washington Hospital Center, Washington, DC, ⁹Albert Einstein College of Medicine, Bronx, NY, ¹⁰University of California San Diego, La Jolla, CA, ¹¹Exagen Inc., Vista, CA, ¹²Loma Linda University and Exagen, Inc, Claremont, CA
Background/Purpose: We reported previously (Ramsey-Goldman et al., Arthritis Rheumatol 2020) that score > 0.8 of a multianalyte assay panel (MAP) with algorithm predicts fulfillment of…
Abstract Number: 1815 • ACR Convergence 2020
Dynamic Changes in Microbiota Representation of a Gut Pathobiont and Clinical Disease Activity in Patients with Lupus Nephritis
Doua Azzouz¹, Ze Chen², Zhi Li³, Peter Izmirly⁴, Jing Deng¹, David Fenyo³, Jill Buyon¹, Alexander Alekseyenko⁵ and Gregg Silverman⁶, ¹Department of Medicine, NYU School of Medicine, New York, NY, ²Department of Microbiology, NYU School of Medicine, New York, NY, ³Institute for Systems Genetics, NYU School of Medicine, New York, NY, ⁴Department of Medicine, New York University School of Medicine, New York, NY, ⁵Medical University of South Carolina, Charleston, SC, ⁶Laboratory of B cell immunobiology, Department of Medicine, NYU School of Medicine, New York, NY
Background/Purpose: From a cross-sectional cohort, we have recently identified a candidate human gut pathobiont, Ruminococcus gnavus (RG) of the Lachnospiraceae family and Blautia genus that…
Abstract Number: 1831 • ACR Convergence 2020
Biomarkers Linked to Anti-IFN-I and Ustekinumab Suggest Distinct Mechanism of Action in Systemic Lupus Erythematosus
Thomas Dörner¹, George Tsokos², Kenneth Kalunian³, Ronald van Vollenhoven⁴, Ashley Orillion⁵, Matteo Cesaroni⁵, Jacqueline Benson⁶, Marc Chevrier⁷, Shawn Rose⁸, Stanley Marciniak⁵, Zhenling Yao⁵, Bhaskar Srivastava⁵, Jessica Schreiter⁵, Frédéric Baribaud⁵, Tatiana Ort⁵, Jarrat Jordan⁵ and Loqmane Seridi⁵, ¹DRFZ and Charité University Hospitals, Berlin, Germany, ²Division of Rheumatology & Clinical Immunology/Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA, ³University of California San Diego, La Jolla, CA, ⁴Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶Janssen Research & Development, LLC, South San Francisco, CA, ⁷Janssen Research & Development, LLC, Collegeville, PA, ⁸Janssen Research & Development, LLC, Princeton Junction, NJ
Background/Purpose: Clinical and biological heterogeneity pose a significant hurdle in SLE, making biomarkers that define patient subsets crucial for developing tailored therapies. Interventional SLE trials…
Abstract Number: 1955 • ACR Convergence 2020
High-throughput Identification of Functional Regulatory SNPs Associated with Systemic Lupus Erythematosus
Qiang Wang¹, Marta Martínez², Matthew Weirauch³ and Peter Nigrovic⁴, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, ³Cincinnati Children’s Hospital Medical Center/Univ of Cincinnati, 535 Terrace Ave, ⁴Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA, Boston
Background/Purpose: Systemic lupus erythematosus (SLE) is a disease involves the complex interplay of many genes, reflected in more than one hundred loci linked with disease…
Abstract Number: 032 • 2020 Pediatric Rheumatology Symposium
The Impact of Psychiatric Diagnosis and Treatment on Medication Adherence in Youth with Systemic Lupus Erythematosus
Joyce Chang¹, Alaina Davis ², Marisa Klein-Gitelman ³, Zuleyha Cidav ⁴, David Mandell ⁵ and Andrea Knight ⁶, ¹Children's Hospital of Philadelphia, Philadelphia, ²Monroe Carell Jr. Children’s Hospital at Vanderbilt, Nashville, Tennessee, ³Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, ⁴University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, ⁵Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ⁶SickKids Research Institute, Toronto, Canada
Background/Purpose: Youth with systemic lupus erythematosus (SLE) experience significant health care burden and high rates of psychiatric disorders. Optimizing medication adherence is critical for preventing…
Abstract Number: 033 • 2020 Pediatric Rheumatology Symposium
Parental Adverse Childhood Experience (ACE) Exposure Is Predictive of Active Lupus in Pediatric Patients
Michael Nelson¹, Nancy Correa ², Ashley Butler ¹, Marietta De Guzman ³, Bethanie Van Horne ¹ and Christopher Greeley ¹, ¹Baylor College of Medicine, Houston, ²Texas Children's Hospital, Houston, ³Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas
Background/Purpose: Adverse Childhood Experiences (ACEs) have been recognized for more than two decades as risk factors for poor health outcomes in adults. Nevertheless, the impact…
Abstract Number: 035 • 2020 Pediatric Rheumatology Symposium
The Childhood and Rheumatology Research Alliance Systemic Lupus Erythematosus and Related Disorders Cohort
Stacy Ardoin¹, Stephen Balevic ², Aimee Hersh ³, Yukiko Kimura ⁴, Andrea Knight ⁵, Laura Schanberg ⁶, Mary Beth Son ⁷ and Timothy Beukelman ⁸ for the CARRA investigators, ¹Nationwide Children's Hospital, Columbus, ²Duke University, Hillsborough, ³University of Utah Primary Children's Hospital, Salt Lake City, ⁴Hackensack Meridian School of Medicine, Hackensack, ⁵SickKids Research Institute, Toronto, Canada, ⁶Duke Children's Hospital & Health Center, Durham, North Carolina, ⁷Boston Children's Hospital, Boston, Massachusetts, ⁸University of Alabama at Birmingham, Birmingham
Background/Purpose: Optimal therapy in childhood onset systemic lupus erythematosus (SLE) lack sufficient data to support clinical decision making. To address this knowledge gap, the Childhood…
Abstract Number: 052 • 2020 Pediatric Rheumatology Symposium
Nasopharyngeal Pneumococcus Colonization in Patients with Childhood Onset Systemic Lupus Erythematosus (cSLE) Compared to Healthy Controls
Fatima Barbar-Smiley¹, Stacy Ardoin ², Chack-Yung Yu ³, Veronica Mruk ⁴, Cagri Yildirim-Toruner ², Vidya Sivaraman ⁵, Joanne Drew ¹, alexa meara ⁶, Asuncion Mejias ² and Octavio Ramilo ⁷, ¹Nationwide Children's Hospital, Columbus, Ohio, ²Nationwide Children's Hospital, Columbus, ³Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, ⁴The Ohio State University, Columbus, ⁵Division of Rheumatology, Nationwide Children's Hospital, Bexley, ⁶The Ohio State University Wexner Medical Center, COLUMBUS, ⁷Nationwide Children's Hospital, 700 Children's Drive
Background/Purpose: Streptococcus pneumoniae (S. pneumoniae) may lead to severe life-threatening infections in both the general and immunocompromised population. Patients diagnosed with Systemic Lupus Erythematosus (SLE)…
Abstract Number: 056 • 2020 Pediatric Rheumatology Symposium
Non-criteria Antiphospholipid Antibodies Associated with Pediatric Rheumatic Disease: A Single-Center Case Series
Shawn Mahmud¹, Danielle Bullock ¹, Colleen Correll ¹, Patricia Hobday ², Mona Riskalla ³, Richard Vehe ⁴ and Bryce Binstadt ¹, ¹University of Minnesota, Minneapolis, ²Minneapolis, ³University of Minnesota, Minneapolis, Minnesota, ⁴University of Minnesota, Roseville
Background/Purpose: Non-criteria antiphospholipid antibodies (NC-aPL) bind molecules such as phosphatidylethanolamine (PE), phosphatidylserine (PS), and prothrombin (Pt), but not the targets of routine antiphospholipid (aPL) testing…
Abstract Number: 075 • 2020 Pediatric Rheumatology Symposium
Pseudotumor Cerebri Syndrome in Children with Systemic Lupus Erythematosus
Taha Moussa¹, Moussa Abdelhak ² and Cuoghi Edens ³, ¹University of Chicago Medicine, Chicago, ²Cambridge GPVTS, Cambridge, United Kingdom, ³University of Chicago, Chicago
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease that typically affects multiple organs and can lead to potentially fatal complications. Management of…
Abstract Number: 083 • 2020 Pediatric Rheumatology Symposium
Worsening Disease Activity and Inability to Taper Corticosteroids in an Ethnically Diverse Cohort of Pediatric-Onset Lupus Patients After Transition to Adult Care
Marla Guzman¹, Anne Eberhard ¹ and Joyce Hui-Yuen ², ¹Cohen Children's Medical Center, Lake Success, ²Cohen Children's Medical Center, New Hyde Park
Background/Purpose: Transition of pediatric lupus (pSLE) patients from pediatric to adult rheumatology care is historically difficult and challenging. We aim to investigate disease activity and…
Abstract Number: 094 • 2020 Pediatric Rheumatology Symposium
A Good Inter- and Intra-observer Reliability of Subtypes in Nailfold Capillary Micro-haemorrhages in Childhood-onset Systemic Lupus Erythematosus
Sandy Bergkamp¹, Dieneke Schonenberg-Meinema ², Merlijn van den Berg ², Vanessa Smith ³, Amber Vanhaecke ⁴, Karin Melsens ⁴, Amara Nassar Sheikh Rashid ⁵, Taco Kuijpers ⁶ and Maartje Boumans ⁷, ¹Amsterdam Medical Center, Uithoorn, Netherlands, ²Amsterdam, Netherlands, ³Ghent University Hospital, Ghent, Belgium, ⁴Ghent University, Ghent, Belgium, ⁵Amsterdam Medical Center, Amsterdam, Netherlands, ⁶AMC, Amsterdam, Netherlands, ⁷Maxima Medical Center, Eindhoven, Netherlands
Background/Purpose: In previous studies, micro-haemorrhages have often been observed in nailfold capillaroscopy in SLE.1 The interpretation of this finding is still a topic of research.…
Abstract Number: 124 • 2020 Pediatric Rheumatology Symposium
Pharmacist Role in an Outpatient Adolescent Complex Pediatric Lupus Clinic
Shannon Rotolo ¹, Grace Cameron², Cuoghi Edens ¹ and Constentina Talevski ³, ¹UCM, Chicago, ²UCM, Oak Lawn, ³Univeristy of Chicago Medicine, Lockport
Background/Purpose: Systemic lupus erythematous (SLE) is an autoimmune disease in which the body produces pathogenic autoantibodies that cause inflammation resulting in multi-organ damage. A SLE…
Abstract Number: 127 • 2020 Pediatric Rheumatology Symposium
Disease Characteristics and Medication Utilization in Lupus Nephritis Associated with Childhood-Onset Systemic Lupus Erythematosus
Emily Smitherman¹, Rouba Chahine ¹, Timothy Beukelman ¹, Laura Lewandowski ², AKM Fazlur Rahman ¹, Scott Wenderfer ³, Aimee Hersh ⁴ and Jeffrey R Curtis ⁵ for the CARRA investigators, ¹University of Alabama at Birmingham, Birmingham, ²NIAMS, NIH, Rockville, ³Section of Nephrology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, ⁴University of Utah Primary Children's Hospital, Salt Lake City, ⁵University of Alabama at Birmingham, Hoover
Background/Purpose: Lupus nephritis associated with childhood-onset systemic lupus erythematosus (cSLE) is a significant risk factor for long-term morbidity and mortality, but little is known regarding…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].